About The Study:

Migraine stands as a prevalent and incapacitating neurological condition, impacting around 15% of the adult populace and ranking as the second highest contributor to years spent grappling with disability on a global scale. This disorder manifests through recurrent, intense, one-sided throbbing headaches that span from 4 to 72 hours. Distinctive features encompass unilateral placement, pulsating sensation, moderate to severe intensity, exacerbation through regular physical tasks, and connection to feelings of nausea and/or heightened sensitivity to light and sound.

At Rochester Clinical Research we are currently seeking participants who are 18 years or older and suffer from migraine attacks to join a migraine treatment study. This is a phase 3 study and its goal is to support approval in the EU by providing additional data showing single-attack efficacy and consistency of intranasal Zavegepant 10mg response, across multiple attacks for the acute treatment of migraine in adult participants.

The study will last about 6 months and include 4 visits to our office along with 3 telephone calls. You will be compensated for your trial-related time if you participate. Study-related care is available to participants at no cost and health insurance is not required nor needed.


  • Must be 18 years or older to participate
  • If you are over 50 years old, a diagnosis of migraines needs to have been made prior to the age of 50
  • Those with Triptan resistance are welcome to apply!
  • Have had a diagnosed history of migraines for at least a year
  • *Please note that other qualifications apply